MINT-URSODIOL 250 MG
URSODIOL : 250 MG · DIN 02449129 · MINT PHARMACEUTICALS INC
Health Canada status: CANCELLED PRE MARKET
What is MINT-URSODIOL?
MINT-URSODIOL 250 MG contains URSODIOL : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02449129, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 17-Nov-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02449129 |
|---|---|
| Brand name | MINT-URSODIOL |
| Generic / active ingredient | URSODIOL : 250 MG |
| Manufacturer | MINT PHARMACEUTICALS INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A05AA02 URSODEOXYCHOLIC ACID |
| AHFS class | 56:14.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 17-Nov-2015 |
What can be used instead?
Other Canadian products sharing ATC code A05AA02 URSODEOXYCHOLIC ACID. 8 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GLN-URSODIOL | 250 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02426900 |
| GLN-URSODIOL | 500 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02426919 |
| JAMP-URSODIOL | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02472392 |
| JAMP-URSODIOL | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02472406 |
| NRA-URSODIOL | 250 MG | TABLET | NORA PHARMA INC | MARKETED | DIN 02544032 |
| NRA-URSODIOL | 500 MG | TABLET | NORA PHARMA INC | MARKETED | DIN 02544024 |
| PMS-URSODIOL C | 250 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02273497 |
| PMS-URSODIOL C | 500 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02273500 |
| AG-URSODIOL | 250 MG | TABLET | ANGITA PHARMA INC. | DORMANT | DIN 02505363 |
| AG-URSODIOL | 500 MG | TABLET | ANGITA PHARMA INC. | DORMANT | DIN 02505371 |
Who else supplies URSODEOXYCHOLIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. URSODEOXYCHOLIC ACID appears in 48 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.